Characterization of cultured cholangiocytes isolated from livers of patients with primary sclerosing cholangitis

Laboratory Investigation

Volumn 94, Issue 10, 2014, Pages 1126-1133

  Tabibian, James H ^a,b   Trussoni, Christy E ^a,b   O'Hara, Steven P ^a,b   Splinter, Patrick L ^a,b   Heimbach, Julie K ^a   LaRusso, Nicholas F ^a,b  

^a MAYO CLINIC   (United States)

^b Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CD31 ANTIGEN; CYTOKERATIN 19; CYTOKERATIN 7; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; BIOLOGICAL MARKER;

ADULT; ARTICLE; CASE REPORT; CELL ADHESION; CELL AGING; CELL ISOLATION; CELL LINE; CELL PROLIFERATION; CELL STRUCTURE; CELLS BY BODY ANATOMY; CHOLANGIOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DISSECTION; ELECTRIC RESISTANCE; FEMALE; FILTRATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMAGNETIC SEPARATION; IN VITRO STUDY; INFLAMMATION; LIVER CELL; MALE; MIDDLE AGED; MYOFIBROBLAST; NEXT GENERATION SEQUENCING; PHENOTYPE; PRIMARY CULTURE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIGHT JUNCTION; TRANSEPITHELIAL ELECTRICAL RESISTANCE; CELL JUNCTION; CELL SEPARATION; LIVER; METABOLISM; PATHOLOGY; SCLEROSING CHOLANGITIS; TUMOR CELL LINE;

BIOLOGICAL MARKERS; CELL AGING; CELL LINE, TUMOR; CELL SEPARATION; CHOLANGITIS, SCLEROSING; FEMALE; HUMANS; INTERCELLULAR JUNCTIONS; LIVER; MALE; MIDDLE AGED;

EID: 84921715676     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2014.94     Document Type: Article

References (37)

1. Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660-678.
2. Tabibian JH, Lindor KD. Primary sclerosing cholangitis: a review and update on therapeutic developments. Exp Rev Gastroenterol Hepatol 2013;7:103-114.
3. Gupta A, Bowlus CL. Primary sclerosing cholangitis: etiopathogenesis and clinical management. Front Biosci 2012;4:1683-1705.
4. Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004;40:472-477.
5. Levy C, Lindor KD. Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. Semin Liver Dis 2006;26:22-30.
6. Brandsaeter B, Broome U, Isoniemi H, et al. Liver transplantation for primary sclerosing cholangitis in the Nordic countries: outcome after acceptance to the waiting list. Liver Transpl 2003;9:961-969.
7. Ali JM, Bonomo L, Brais R, et al. Outcomes and diagnostic challenges posed by incidental cholangiocarcinoma after liver transplantation. Transplantation 2011;91:1392-1397.
8. Landaverde C, Ng V, Sato A, et al. De-novo cholangiocarcinoma in native common bile duct remnant following OLT for primary sclerosing cholangitis. Ann Hepatol 2009;8:379-383.
9. Tabibian JH, Macura SI, O'Hara SP, et al. Micro-computed tomography and nuclear magnetic resonance imaging for noninvasive, live-mouse cholangiography. Lab Invest 2013;93:733-743.
10. Fickert P, Zollner G, Fuchsbichler A, et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002;123:1238-1251.
11. Yamada S, Ishii M, Liang LS, et al. Small duct cholangitis induced by N-formyl L-methionine L-leucine L-tyrosine in rats. J Gastroenterol 1994;29:631-636.
12. Pollheimer MJ, Trauner M, Fickert P. Will we ever model PSC?-"it's hard to be a PSC model!". Clin Res Hepatol Gastroenterol 2011;35:792-804.
13. Weismuller TJ, Wedemeyer J, Kubicka S, et al. The challenges in primary sclerosing cholangitis-aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol 2008;48(Suppl 1):S38-S57.
14. Tabibian JH, Talwalkar JA, Lindor KD. Role of the microbiota and antibiotics in primary sclerosing cholangitis. Biomed Res Int 2013;2013:389537.
15. Alpini G, Phillips JO, Vroman B, et al. Recent advances in the isolation of liver cells. Hepatology 1994;20:494-514.
16. Tabibian JH, O'Hara SP, Splinter PL, et al. Cholangiocyte senescence via N-Ras activation is a characteristic of primary sclerosing cholangitis. Hepatology 2014;59:2263-2275.
17. Wiesner RH, LaRusso NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980;79:200-206.
18. Vitellas KM, Keogan MT, Freed KS, et al. Radiologic manifestations of sclerosing cholangitis with emphasis on MR cholangiopancrea-tography. Radiographics 2000;20:959-975, quiz 1108-9, 1112.
19. O'Hara SP, Splinter PL, Trussoni CE, et al. Cholangiocyte N-Ras protein mediates lipopolysaccharide-induced interleukin 6 secretion and proliferation. J Biol Chem 2011;286:30352-30360.
20. Sasaki M, Ikeda H, Haga H, et al. Frequent cellular senescence in small bile ducts in primary biliary cirrhosis: a possible role in bile duct loss. J Pathol 2005;205:451-459.
21. Karrar A, Broome U, Sodergren T, et al. Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis. Gastroenterology 2007;132:1504-1514.
22. Banales JM, Saez E, Uriz M, et al. Up-regulation of microRNA 506 leads to decreased Cl-/HCO3-anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology 2012;56:687-697.
23. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995;92:9363-9367.
24. Craig TA, Zhang Y, McNulty MS, et al. Research resource: whole transcriptome RNA sequencing detects multiple 1alpha, 25-dihydroxyvitamin D(3)-sensitive metabolic pathways in developing zebrafish. Mol Endocrinol 2012;26:1630-1642.
25. Bullard JH, Purdom E, Hansen KD, et al. Evaluation of statistical methods for normalization and differential expression in mRNA-Seq experiments. BMC Bioinform 2010;11:94.
26. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol 2010;11:R106.
27. Joplin R, Strain AJ, Neuberger JM. Biliary epithelial cells from the liver of patients with primary biliary cirrhosis: isolation, characterization, and short-term culture. J Pathol 1990;162:255-260.
28. Gall JA, Bhathal PS. The isolation of intrahepatic biliary epithelial cells from normal rat livers. Cell Biol Int Rep 1985;9:315-322.
29. Grant AG, Billing BH. The isolation and characterization of a bile ductule cell population from normal and bile-duct ligated rat livers. Br J Exp Pathol 1977;58:301-310.
30. Joplin R, Strain AJ, Neuberger JM. Immuno-isolation and culture of biliary epithelial cells from normal human liver. In Vitro Cell Dev Biol 1989;25:1189-1192.
31. Alpini G, Lenzi R, Zhai WR, et al. Isolation of a nonparenchymal liver cell fraction enriched in cells with biliary epithelial phenotypes. Gastroenterology 1989;97:1248-1260.
32. Madara JL. Tight junction dynamics: is paracellular transport regulated? Cell 1988;53:497-498.
33. Muff MA, Masyuk TV, Stroope AJ, et al. Development and characterization of a cholangiocyte cell line from the PCK rat, an animal model of autosomal recessive polycystic kidney disease. Lab Invest 2006;86:940-950.
34. Washington K, Clavien PA, Killenberg P. Peribiliary vascular plexus in primary sclerosing cholangitis and primary biliary cirrhosis. Hum Pathol 1997;28:791-795.
35. Fickert P, Fuchsbichler A, Wagner M, et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2004;127:261-274.
36. O'Hara SP, Tabibian JH, Splinter PL, et al. The dynamic biliary epithelia: molecules, pathways, and disease. J Hepatol 2013;58: 575-582.
37. Han Y, Glaser S, Meng F, et al. Recent advances in the morphological and functional heterogeneity of the biliary epithelium. Exp Biol Med (Maywood) 2013;238:549-565.